Cover Image
市場調查報告書

PharmaPoint:重度憂鬱症 - 現在/未來的主要企業

PharmaPoint: Major Depressive Disorder - Current and Future Players

出版商 GlobalData 商品編碼 305491
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:重度憂鬱症 - 現在/未來的主要企業 PharmaPoint: Major Depressive Disorder - Current and Future Players
出版日期: 2014年05月30日 內容資訊: 英文 59 Pages
簡介

本報告提供急速成長中的全球重度憂鬱症治療藥市場相關資料,以包含新加入之競爭情勢為焦點,彙整競爭評估,企業簡介,營業內容,財務狀況,策略評估與未來方案等詳細分析。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Lundbeck
    • Forest Laboratories (Actavis)
    • Eli Lilly
    • Pfizer
    • 大塚製藥
    • AstraZeneca
    • 武田醫藥品
    • Alkermes
    • Euthymics Bioscience
    • Naurex
    • e-Therapeutics

第5章 附錄

圖表

目錄
Product Code: GDHC1035FPR

GlobalData has released its pharma report, "PharmaPoint: Major Depressive Disorder - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Major Depressive Disorder.
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • What's the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Related Reports

3. Market Outlook

  • 3.1 Global
    • 3.1.1 Forecast
    • 3.1.2 Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1 Overview
  • 4.2 Trends in Corporate Strategy
  • 4.3 Company Profiles
    • 4.3.1 Lundbeck
    • 4.3.2 Forest Laboratories (Actavis)
    • 4.3.3 Eli Lilly
    • 4.3.4 Pfizer
    • 4.3.5 Otsuka Pharmaceutical
    • 4.3.6 AstraZeneca
    • 4.3.7 Takeda Pharmaceutical
    • 4.3.8 Alkermes
    • 4.3.9 Euthymics Bioscience
    • 4.3.10 Naurex
    • 4.3.11 e-Therapeutics

5. Appendix

  • 5.1 Bibliography
  • 5.2 Abbreviations
  • 5.3 Methodology
  • 5.4 Forecasting Methodology
    • 5.4.1 Diagnosed MDD Patients
    • 5.4.2 Percent of Drug-Treated Patients
    • 5.4.3 General Pricing Assumptions
    • 5.4.4 Generic Erosion
  • 5.5 Physicians and Specialists Included in this Study
  • 5.6 About the Authors
    • 5.6.1 Analyst
    • 5.6.2 Therapy Area Directors
    • 5.6.3 Global Head of Healthcare
  • 5.7 About GlobalData
  • 5.8 Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($) for MDD, 2013-2023
  • Table 2: MDD Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the MDD Market in the 7MM and Australia, 2013
  • Table 4: Lundbeck's MDD Portfolio Assessment, 2013
  • Table 5: Forest (Actavis)'s MDD Portfolio Assessment, 2013
  • Table 6: Eli Lilly's MDD Portfolio Assessment, 2013
  • Table 7: Pfizer's MDD Portfolio Assessment, 2013
  • Table 8: Otsuka's MDD Portfolio Assessment, 2013
  • Table 9: AstraZeneca's MDD Portfolio Assessment, 2013
  • Table 10: Takeda's MDD Portfolio Assessment, 2013
  • Table 11: Alkermes's MDD Portfolio Assessment, 2013
  • Table 12: Euthymics Bioscience's MDD Portfolio Assessment, 2013
  • Table 13: Naurex's MDD Portfolio Assessment, 2013
  • Table 14: e-Therapeutics's MDD Portfolio Assessment, 2013
  • Table 15: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for MDD by Region, 2013-2023
  • Figure 2: Company Portfolio Gap Analysis in MDD, 2013-2023
  • Figure 3: Lundbeck SWOT Analysis in MDD, 2013-2023
  • Figure 4: Forest (Actavis) SWOT Analysis in MDD, 2013-2023
  • Figure 5: Eli Lilly SWOT Analysis in MDD, 2013-2023
  • Figure 6: Pfizer SWOT Analysis in MDD, 2013-2023
  • Figure 7: Otsuka SWOT Analysis in MDD, 2013-2023
  • Figure 8: AstraZeneca SWOT Analysis in MDD, 2013-2023
  • Figure 9: Takeda SWOT Analysis in MDD, 2013-2023
  • Figure 10: Alkermes SWOT Analysis in MDD, 2013-2023
  • Figure 11: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023
  • Figure 12: Naurex SWOT Analysis in MDD, 2013-2023
  • Figure 13: e-Therapeutics SWOT Analysis in MDD, 2013-2023
Back to Top